Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
about
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.AKT signaling in ERBB2-amplified breast cancer.Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast CancerLapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Protein Kinase Targets in Breast Cancer.Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field
P2860
Q36545717-C69FB0C6-0356-448D-88B9-36E5E3B33EBEQ36563578-C4473D79-A147-4D82-9010-3FA180E76243Q36963374-98FDB52C-0D76-42EC-9CAF-2F08EDD7613FQ38812867-B2269E73-D4CC-4763-B836-7F843E484B29Q38888022-1DA69E57-1A15-4158-9402-E1AFF900B876Q39421814-E5557AC7-DCC4-4996-8886-69DD8D08B4E6Q41149668-56D12E77-0724-4B48-8144-6342D8CC3B7BQ47351355-38D8D0E4-FEDC-478C-B538-E155788187EAQ48354684-D519A631-A046-4E25-A8C8-FD7543542212Q51016839-C486C40F-CEE7-4DEB-A520-AC895F7BC657Q57495764-C2067EF2-8892-43ED-AEF1-FA58E2A754EB
P2860
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefit to neoadjuvant anti-hu ...... m chromosome 10 (PTEN) status.
@en
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2
@nl
type
label
Benefit to neoadjuvant anti-hu ...... m chromosome 10 (PTEN) status.
@en
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2
@nl
prefLabel
Benefit to neoadjuvant anti-hu ...... m chromosome 10 (PTEN) status.
@en
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2
@nl
P2093
P2860
P356
P1433
P1476
Benefit to neoadjuvant anti-hu ...... m chromosome 10 (PTEN) status.
@en
P2093
H Eidtmann
L de la Peña
M J Piccart-Gebhart
M Scaltriti
P2860
P304
P356
10.1093/ANNONC/MDV175
P50
P577
2015-04-07T00:00:00Z